Диссертация (Сравнительная оценка безопасности дабигатрана, ривароксабана и апиксабана у пациентов с фибрилляцией предсердий неклапанной этиологии), страница 19
Описание файла
Файл "Диссертация" внутри архива находится в папке "Сравнительная оценка безопасности дабигатрана, ривароксабана и апиксабана у пациентов с фибрилляцией предсердий неклапанной этиологии". PDF-файл из архива "Сравнительная оценка безопасности дабигатрана, ривароксабана и апиксабана у пациентов с фибрилляцией предсердий неклапанной этиологии", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата медицинских наук.
Просмотр PDF-файла онлайн
Текст 19 страницы из PDF
Bleeding Events Associated with Novel Anticoagulants: A CaseSeries. // Heart, Lung and Circulation 2013;22:1043-1047.96.Samama M.M., Martinoli J.L., LeFlem L., Guinet C., Plu-Bureau G., Depasse F.,Perzborn E. Assessment of laboratory assays to measure rivaroxaban – an oral,direct fac tor Xa inhibitor.
// Thromb Haemost.2010;103:815–825.97.Savelieva I. et al. Ann Med 2007; 39:371–91.98.Siegbahn A. et al. D-dimer and factor VIIa in atrial fibrillation - prognostic valuesfor cardiovascular events and effects of anticoagulation therapy. A RE-LY120substudy. // Thromb Haemost. 2016 May 2;115(5):921-30. doi: 10.1160/TH15-070529. Epub 2016 Jan 28.99.Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence,and predictors of atrial fibrillation in the Renfrew/ Paisley study.
// Heart 2001; 86:516–521.100.Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 riskstratification schemes to predict stroke in patients with nonvalvular atrialfibrillation. // Stroke. – 2008. – Vol. 39. P. 1901–10.101.Stroke Risk in Atrial Fibrillation Working Group. Independent predictors ofstroke in patients with atrial fibrillation: a systematic review. // Neurology. – 2007.Vol.
69. – P.546–554.102.Tepper P. et al. Real-world comparison of bleeding risks among non-valvularatrial fibrillation patients on apixaban, dabigatran, rivaroxaban: cohorts comprisingnew initiators and/or switchers from warfarin. // Eur Heart J. 2015;36:AbstractSupplement 339.103.Tobu M., Iqbal O., Hoppensteadt D., Neville B., Messmore H.L., Fareed J.Anti-Xa and anti-IIa drugs alter international normalized ratio measurements:potential problems in the monitoring of oral anticoagulants. // Clin Appl ThrombHemost.
2004;10:301–309.104.Tripodi A., Chantarangkul V., Guinet C., Samama M.M. The InternationalNormalized Ratio calibrated for rivaroxaban has the potential to normalizeprothrombin time results for rivaroxaban-treated patients: results of an in vitrostudy. // J Thromb Haemost. 2011;9:226–228.105.Tripodi A., Padovan L., Testa S., Legnani C., Chantarangkul V.
How thedirect oral anticoagulant apixaban affects hemostatic parameters. Results of amulticenter multiplatform study. // Clin Chem Lab Med. 2015 Feb;53(2):265-73.106.Ucar H. I., M. Oc, M. Tok, O. F. Dogan, B. Oc, A. Aydin, B. Farsak, M.Guvener, A. C. Yorgancioglu, R. Dogan, M. Demircin and I. Pasaoglu (2007)."Preoperative fibrinogen levels as a predictor of postoperative bleeding after openheart surgery." Heart Surg Forum 10(5): E392-396.121107.Van Ryn J., Sieger P., Kink-Eiband M., et al. New Orleans, LA: 2009.Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasmaby activated charcoal in vitro. Paper presented at 51st American Society ofHematology Annual Meeting and Exposition.
Suryanarayan D, Schulman S.Potential antidotes for reversal of old and new oral anticoagulants.Thromb Res.2014;133:S158–S166.108.Van Ryn .J, Stangier J., Haertter S., Liesenfeld K.H., Wienen W., FeuringM., Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombininhibitor: interpretation of coagulation assays and reversal of anticoagulantactivity. // Thromb Haemost. 2010;103:1116–1127.109.Ward .F, McGovern R., Cotter P.E.
Troponin-I is a predictor of a delayeddiagnosis of atrial fibrillation in acute ischemic stroke and transient ischemicattack. // J Stroke Cerebrovasc Dis 2015; 24:66–72.110.Warkentin T.E., Margetts P., Connolly S.J., Lamy A., Ricci C., EikelboomJ.W. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massivedabigatran-associated postcardiac surgery bleeding. // Blood.2012;119:2172–2174.111.Weitz J.
I. New oral anticoagulants in development. // Thromb Haemost.2010;103:62-70.112.Westendorf J., Ageno W. Benefit-risk profile of non-vitamin K antagonistoral anticoagulants in the management of venous thromboembolism. // ThrombHaemost.2014;16:113–128.Ridgefield,CT:BoehringerIngelheimPharmaceuticals; 2011.113.Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independentrisk factor for stroke: the Framingham Study. // Stroke.
1991. Vol. 22. P. 983–988.114.Wong P.C., Crain E.J., Watson C.A., Xin B. Favorable therapeutic index ofthe direct factor Xa inhibitors, apixaban and rivaroxaban, compared with thethrombin inhibitor dabigatran in rabbits. // J Thromb Haemost.2009;7:1313–1320.122115.Wychowski M.K., Kouides P.A. Dabigatran-induced gastrointestinalBleeding in an elderly patient with moderate renal impairment. // AnnPharmacother. 2012;46:e10.116.Yeo C.H., Eranki V., Pillai A., Morrison G. Rivaroxaban and its Effect onInternational Normalised Ratio-A Prospective Study of 28 Hip and KneeArthroplasty Patients.
// American Medical Journal. 2012;3:126–129.117.Ziad Hijazi, Agneta Siegbahn, Ulrika Andersson, Christopher B. Granger,John H. Alexander, Dan Atar, Bernard J. Gersh, Puneet Mohan, Veli-PekkaHarjola, John Horowitz, Steen Husted, Elaine M. Hylek, Renato D. Lopes, JohnJ.V. McMurray, Lars Wallentin. High-sensitivity troponin I for risk assessment inpatients with atrial fibrillation: insights from the Apixaban for Reduction in Strokeand Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. //Circulation 2014; 129:625–634.118.Ziad Hijazi et al.
The novel biomarker-based ABC (age, biomarkers, clinicalhistory)-bleeding risk score for patients with atrial fi brillation: a derivation andvalidation study. // Lancet 2016; 387: 2302–11..
